Skip to main content
Erschienen in:

24.09.2020 | Peritoneal Surface Malignancy

Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases

verfasst von: Dario Baratti, MD, Shigeki Kusamura, PhD, Monica Niger, MD, Federica Perrone, PhD, Massimo Milione, MD, Laura Cattaneo, MD, Marcello Guaglio, MD, Valentina Bartolini, MD, Filippo Pietrantonio, MD, Marcello Deraco, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Selecting patients with colorectal cancer peritoneal metastases (CRC-PMs) for surgery is still a concern. Biological features have the potential to improve prognostic stratification, but their significance in this clinical setting is still unclear. We assessed the prognostic impact of primary side and KRAS/NRAS/BRAF/PIK3CA mutations in patients treated with either cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) or CRS alone.

Methods

We reviewed a prospective database of 152 CRC-PM patients selected to undergo perioperative systemic chemotherapy and CRS with or without HIPEC. Extensive mutational analysis of KRAS, NRAS, BRAF, and PIK3CA was performed by polymerase chain reaction (PCR). In 68 patients, Ion Torrent next-generation sequencing technology was used to characterize the hotspot regions of 50 genes.

Results

The primary tumor was right-sided in 61 patients (40.1%) and left-sided in 91 patients (59.9%). Right-sided primaries were associated with mutated KRAS (p = 0.01) and normal carcinoembryonic antigen (CEA; p = 0.03). KRAS was mutated in 71/152 patients (46.7%), NRAS in 7/152 patients (4.6%), BRAF in 10/152 patients (6.6%), PIK3CA in 17/78 patients (25.0%), TP53 in 37/68 patients (54.4%), APC in 25/68 patients (36.7%), SMAD4 in 13/68 patients (19.1%), and FBXW7 in 5/68 patients (7.4%). Median follow-up was 54.9 months and median survival from PM diagnosis was 45.1 months. The right-sided primary (hazard ratio [HR] 1.62, 95% confidence interval [CI] 0.43–0.89; p = 0.011), BRAF mutations (HR 2.21, 95% CI 1.05–4.63; p = 0.038), and Peritoneal Cancer Index (HR 1.47, 95% CI 1.03–2.10; p = 0.036) independently correlated with poorer survival, while APC mutations univariately correlated with better survival (p = 0.03).

Conclusions

BRAF mutations and right-sided primary are adverse prognostic factors that may be used to optimize therapeutic strategies. APC may be involved in CRC-PM development and progression.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128:2717–25.PubMed Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128:2717–25.PubMed
2.
Zurück zum Zitat Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99:699–705.PubMed Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99:699–705.PubMed
3.
Zurück zum Zitat Baratti D, Kusamura S, Pietrantonio F, et al. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review. Crit Rev Oncol Hematol. 2016;100:209–22.PubMed Baratti D, Kusamura S, Pietrantonio F, et al. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review. Crit Rev Oncol Hematol. 2016;100:209–22.PubMed
4.
Zurück zum Zitat Franko J, Shi Q, Meyers JP, et al. Analysis and research in cancers of the digestive system (ARCAD) Group. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016;17:1709–19PubMed Franko J, Shi Q, Meyers JP, et al. Analysis and research in cancers of the digestive system (ARCAD) Group. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016;17:1709–19PubMed
5.
Zurück zum Zitat Klaver YL, Simkens LH, Lemmens VE, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38:617–23.PubMed Klaver YL, Simkens LH, Lemmens VE, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38:617–23.PubMed
6.
Zurück zum Zitat Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.PubMed Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.PubMed
7.
Zurück zum Zitat Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMed Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMed
8.
Zurück zum Zitat Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.PubMed Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.PubMed
9.
Zurück zum Zitat Cashin PH, Mahteme H, Spång N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer. 2016;53:155–62.PubMed Cashin PH, Mahteme H, Spång N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer. 2016;53:155–62.PubMed
10.
Zurück zum Zitat Cremolini C, Antoniotti C, Moretto R, et al. First-line therapy for mCRC—the influence of primary tumour location on the therapeutic algorithm. Nat Rev Clin Oncol. 2017;14:113.PubMed Cremolini C, Antoniotti C, Moretto R, et al. First-line therapy for mCRC—the influence of primary tumour location on the therapeutic algorithm. Nat Rev Clin Oncol. 2017;14:113.PubMed
11.
Zurück zum Zitat Lipsyc M, Yaeger R. Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol. 2015;6:645–9.PubMedPubMedCentral Lipsyc M, Yaeger R. Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol. 2015;6:645–9.PubMedPubMedCentral
12.
Zurück zum Zitat Karagkounis G, Torbenson MS, Daniel HD, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013;119:4137–44.PubMedPubMedCentral Karagkounis G, Torbenson MS, Daniel HD, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013;119:4137–44.PubMedPubMedCentral
13.
Zurück zum Zitat Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619–26. (discussion 626–627)PubMed Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619–26. (discussion 626–627)PubMed
14.
Zurück zum Zitat Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3:211–9.PubMed Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3:211–9.PubMed
15.
Zurück zum Zitat Baratti D, Scivales A, Balestra MR, et al. Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol. 2010;36:463–9.PubMed Baratti D, Scivales A, Balestra MR, et al. Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol. 2010;36:463–9.PubMed
16.
Zurück zum Zitat Baratti D, Kusamura S, Mingrone E, et al. Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2012;256:334–41.PubMed Baratti D, Kusamura S, Mingrone E, et al. Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2012;256:334–41.PubMed
17.
Zurück zum Zitat Baratti D, Kusamura S, Iusco D, et al. Should a history of extra-peritoneal disease be a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer peritoneal metastases? Dis Colon Rectum. 2018;61:1026–34.PubMed Baratti D, Kusamura S, Iusco D, et al. Should a history of extra-peritoneal disease be a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer peritoneal metastases? Dis Colon Rectum. 2018;61:1026–34.PubMed
18.
Zurück zum Zitat Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–1422.PubMed Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–1422.PubMed
19.
Zurück zum Zitat Deraco M, Baratti D, Kusamura S, et al. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321–8.PubMed Deraco M, Baratti D, Kusamura S, et al. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321–8.PubMed
20.
Zurück zum Zitat Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49–58. Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49–58.
21.
Zurück zum Zitat Schirripa M, Biason P, Lonardi S, et al. Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: a detailed clinical, pathologic, and molecular characterization. Clin Cancer Res. 2019;25:3954–61.PubMed Schirripa M, Biason P, Lonardi S, et al. Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: a detailed clinical, pathologic, and molecular characterization. Clin Cancer Res. 2019;25:3954–61.PubMed
22.
Zurück zum Zitat Kwakman R, Schrama AM, van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg. 2016;263:1102–11.PubMed Kwakman R, Schrama AM, van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg. 2016;263:1102–11.PubMed
23.
Zurück zum Zitat Gillern SM, Chua TC, Stojadinovic A, et al. KRAS Status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome. Am J Clin Oncol. 2010;33:456–60.PubMed Gillern SM, Chua TC, Stojadinovic A, et al. KRAS Status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome. Am J Clin Oncol. 2010;33:456–60.PubMed
24.
Zurück zum Zitat Bruin SC, He Y, Mikolajewska-Hanclich I, et al. Molecular alterations associated with liver metastases development in colorectal cancer patients. Br J Cancer. 2011;105:281–7.PubMedPubMedCentral Bruin SC, He Y, Mikolajewska-Hanclich I, et al. Molecular alterations associated with liver metastases development in colorectal cancer patients. Br J Cancer. 2011;105:281–7.PubMedPubMedCentral
25.
Zurück zum Zitat Massalou D, Benizri E, Chevallier A, et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017 213, 377–87.PubMed Massalou D, Benizri E, Chevallier A, et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017 213, 377–87.PubMed
26.
Zurück zum Zitat Passot G, Kim BJ, Glehen O, et al. Impact of RAS mutations in metastatic colorectal cancer after potentially curative resection: does site of metastases matter? Ann Surg Oncol. 2018;25:179–87PubMed Passot G, Kim BJ, Glehen O, et al. Impact of RAS mutations in metastatic colorectal cancer after potentially curative resection: does site of metastases matter? Ann Surg Oncol. 2018;25:179–87PubMed
27.
Zurück zum Zitat Ubink I, van Eden WJ, Snaebjornsson P, et al. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Br J Surg. 2018;105:e204–11PubMed Ubink I, van Eden WJ, Snaebjornsson P, et al. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Br J Surg. 2018;105:e204–11PubMed
28.
Zurück zum Zitat Schneider MA, Eden J, Pache B, et al. Mutations of RAS/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg. 2018;268:845–53.PubMed Schneider MA, Eden J, Pache B, et al. Mutations of RAS/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg. 2018;268:845–53.PubMed
29.
Zurück zum Zitat Morgan Z, Chow BE, Strong EA, et al. RAS Mutation status confers prognostic relevance in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer. J Surg Res. 2019;240:130–5.PubMed Morgan Z, Chow BE, Strong EA, et al. RAS Mutation status confers prognostic relevance in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer. J Surg Res. 2019;240:130–5.PubMed
30.
Zurück zum Zitat Arjona-Sanchez A, Rodriguez-Ortiz L, Baratti D, et al. RAS mutation decreases overall survival after optimal cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of colorectal peritoneal metastasis: a modification proposal of the peritoneal surface disease severity score. Ann Surg Oncol. 2019;76:2595–604. Arjona-Sanchez A, Rodriguez-Ortiz L, Baratti D, et al. RAS mutation decreases overall survival after optimal cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of colorectal peritoneal metastasis: a modification proposal of the peritoneal surface disease severity score. Ann Surg Oncol. 2019;76:2595–604.
31.
Zurück zum Zitat Graf W, Cashin PH, Ghanipour L, et al. Prognostic impact of BRAF and KRAS mutation in patients with colorectal and appendiceal peritoneal metastases scheduled for CRS and HIPEC. Ann Surg Oncol. 2020;27:293–300.PubMed Graf W, Cashin PH, Ghanipour L, et al. Prognostic impact of BRAF and KRAS mutation in patients with colorectal and appendiceal peritoneal metastases scheduled for CRS and HIPEC. Ann Surg Oncol. 2020;27:293–300.PubMed
32.
Zurück zum Zitat Kelly KJ, Alsayadnasser M, Vaida F, et al. Does primary tumor side matter in patients with metastatic colon cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol. 2019;26:1421–7.PubMed Kelly KJ, Alsayadnasser M, Vaida F, et al. Does primary tumor side matter in patients with metastatic colon cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol. 2019;26:1421–7.PubMed
33.
Zurück zum Zitat Kotha NV, Baumgartner JM, Veerapong J, et al. Primary tumor sidedness is predictive of survival in colon cancer patients treated with cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: A US HIPEC collaborative study. Ann Surg Oncol. 2019;26:2234–40.PubMed Kotha NV, Baumgartner JM, Veerapong J, et al. Primary tumor sidedness is predictive of survival in colon cancer patients treated with cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: A US HIPEC collaborative study. Ann Surg Oncol. 2019;26:2234–40.PubMed
34.
Zurück zum Zitat Péron J, Mercier F, Tuech JJ, et al; on behalf BIG-RENAPE working groups. The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis. Surgery. 2019;165:476–84. Péron J, Mercier F, Tuech JJ, et al; on behalf BIG-RENAPE working groups. The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis. Surgery. 2019;165:476–84.
35.
Zurück zum Zitat Yaeger R, Chatila WK, Lipsyc MD, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell. 2018;33:125–36.e3 Yaeger R, Chatila WK, Lipsyc MD, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell. 2018;33:125–36.e3
36.
Zurück zum Zitat Pietrantonio F, Perrone F, Mennitto A, et al. Toward the molecular dissection of peritoneal pseudomyxoma. Ann Oncol. 2016;27:2097–103.PubMed Pietrantonio F, Perrone F, Mennitto A, et al. Toward the molecular dissection of peritoneal pseudomyxoma. Ann Oncol. 2016;27:2097–103.PubMed
37.
Zurück zum Zitat Goere D, Glehen O, Quenet F, et al. Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP–NTC01226394). J Clin Oncol. 2018;36 Suppl:3531. Goere D, Glehen O, Quenet F, et al. Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP–NTC01226394). J Clin Oncol. 2018;36 Suppl:3531.
38.
Zurück zum Zitat Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4:761–70PubMed Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4:761–70PubMed
39.
Zurück zum Zitat Sasaki Y, Hamaguchi Y, Yamada Y, et al. Value of KRAS, BRAF, and PIK3CA mutations and survival benefit from systemic chemotherapy in colorectal peritoneal carcinomatosis. Asian Pac J Cancer Prev. 2016;17:539–43.PubMed Sasaki Y, Hamaguchi Y, Yamada Y, et al. Value of KRAS, BRAF, and PIK3CA mutations and survival benefit from systemic chemotherapy in colorectal peritoneal carcinomatosis. Asian Pac J Cancer Prev. 2016;17:539–43.PubMed
40.
Zurück zum Zitat Christensen TD, Palshof JA, Larsen FO, et al. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. Acta Oncol. 2018;57:1057–62.PubMed Christensen TD, Palshof JA, Larsen FO, et al. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. Acta Oncol. 2018;57:1057–62.PubMed
41.
Zurück zum Zitat Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.PubMedPubMedCentral Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.PubMedPubMedCentral
42.
Zurück zum Zitat Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7 trial. J Clin Oncol. 2018;36 Suppl:1. Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7 trial. J Clin Oncol. 2018;36 Suppl:1.
43.
Zurück zum Zitat Baratti D, Kusamura S, Azmi N, et al. Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without mitomycin C-based HIPEC: a comparative study using the peritoneal surface disease severity score (PSDSS). Ann Surg Oncol. 2020;27:98–106.PubMed Baratti D, Kusamura S, Azmi N, et al. Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without mitomycin C-based HIPEC: a comparative study using the peritoneal surface disease severity score (PSDSS). Ann Surg Oncol. 2020;27:98–106.PubMed
Metadaten
Titel
Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases
verfasst von
Dario Baratti, MD
Shigeki Kusamura, PhD
Monica Niger, MD
Federica Perrone, PhD
Massimo Milione, MD
Laura Cattaneo, MD
Marcello Guaglio, MD
Valentina Bartolini, MD
Filippo Pietrantonio, MD
Marcello Deraco, MD
Publikationsdatum
24.09.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09161-7

Neu im Fachgebiet Chirurgie

Ab sofort gelten die neuen Verordnungsausnahmen für Lipidsenker

Freie Fahrt für Lipidsenker? Das nicht, doch mit niedrigerem Schwellenwert fürs Infarktrisiko und neuen Indikationen hat der G-BA die Verordnungs-Handbremse ein gutes Stück weit gelockert.

Appendizitis und Darminfarkt durch Blinddarm-Lipom

Eigentlich sind Lipome recht harmlos. Im Zäkum können sie jedoch erhebliche Komplikationen mit Darminfarkt und Appendizitis verursachen.

Gluteuslappen nach Rektumkarzinom-Op. schützt vor Abszessen

Die Wunddeckung mit einem autologen Rotationslappen nach Entfernung eines Rektumkarzinoms konnte in einer randomisierten Studie gegenüber dem primären Wundverschluss vor allem in einer Hinsicht punkten: Sie führte deutlich seltener zu präsakralen Abszessen.

MedTalk Leitlinie KOMPAKT: S3-Leitline zu peripheren Nervenverletzungen

  • Webinar | 10.02.2025 | 13:00

Über den Weg zur finalen Fassung der S3-Leitlinie "Versorgung peripherer Nervenverletzungen" sprechen Prof. Dr. Leila Harhaus-Wähner und Ressortleiter Dr. Gunter Freese im WebTalk Leitlinie KOMPAKT, einer neuen Webcast-Serie von SpringerMedizin passend zu Ihrem Fachmagazin Orthopädie und Unfallchirurgie Mitteilungen und Nachrichten. In dem kurzen Video geht es darum, was sich im Vergleich zur vorigen Fassung der Leitlinie geändert hat, welche Aspekte für die tägliche Praxis besonders wichtig sind und was jeder gemäß Leitlinie nun anders oder besser machen sollte.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.